Brad Sitko
Chief Investment Officer at Xoma NASDAQ: XOMA www.xoma.com
New York, New York, United States
Find your path to Brad
336 people in our graph share verified history with Brad β schools, employers, funds. One of them is your warm intro.
Kesha CashunlockedBrad: together at Columbia Business School (2008β2009)
Γ5Brad: together at University of Pennsylvania
Γ3Brad: together at Columbia Business School
Brad: together at Dnanexus
Chief Investment Officer at Xoma NASDAQ: XOMA www.xoma.com
Intro paths
β
In turn, Brad can intro founders to Xoma NASDAQ: XOMA www.xoma.com's investors below.
Xoma NASDAQ: XOMA www.xoma.com's investors Β· 1
Experience
- XOMA RoyaltyChief Investment Officercurrent2023 β presentNew York, New York, United States
- RTW Investments ICAVDirector (Board Member)2021 β 2023Dublin, County Dublin, Ireland
- RTW Investments, LPManaging Director, Strategic Finance2019 β 2023Greater New York City Area
- CORXEL PharmaceuticalsChief Financial Officer2019 β 2023Shanghai, China
- DNAnexusVice President, Finance, Operations & Corporate Development (Acting CFO/COO)2015 β 2019Mountain View, CA
- MTS Health PartnersDirector, Healthcare Investment Banking2008 β 2015Greater New York City Area
- PfizerAssociate - WW Strategic Planning & Innovation2008
- PfizerAssociate - Business Development - Portfolio & Decision Analysis (PDA)2008
- The Frankel Group / BioDevelopment VenturesConsultant2005 β 2007Greater New York City Area
- DatamonitorAnalyst - Healthcare Consulting & Strategic Insight2003 β 2005
- Lobeman GroupDirector of Sales & Marketing2003
Skills & more
MergersFinancial ModelingCorporate DevelopmentRoyalty MonetizationValuationPrivate PlacementsDCFRestructuringCompetitive AnalysisStrategic PlanningLicensingPortfolio Optimization
+12 more
Corporate FinancePIPEsDue DiligenceMergers & AcquisitionsVenture CapitalMarket ResearchStart-upsInvestment BankingAnalyticsInvestmentsStrategyBusiness DevelopmentFrom Brad's professional profile.
Frequently asked questions
- Who is Brad Sitko?
- Chief Investment Officer at Xoma NASDAQ: XOMA www.xoma.com
- Where does Brad Sitko work?
- Brad Sitko is Chief Investment Officer at Xoma NASDAQ: XOMA www.xoma.com.
- Where did Brad Sitko go to school?
- Brad Sitko studied at Columbia Business School (MBA, Finance, Healthcare and Pharmaceutical Management); University of Pennsylvania (BA, History and Sociology of Science (Bioethics)); Midpark High School.
Same school
Also attended Columbia Business School1,173
Ryan PetersenFounder & CEO of FlexportAryo TehranianManaging Director at Mayfair Equity PartnersYibo NianInvestment Director at Intel CapitalKesha CashFounder & General Partner at Impact America FundMahati SridharPartner, Rise of the Rest at RevolutionGiuseppe IademarcoHead of Global Partnership at P101 Ventures
+ 1,167 more
Also attended University of Pennsylvania1,419
Brian ActonCo-founder of WhatsApp; co-founder of Signal FoundationKunal BahlCo-founder of Snapdeal; co-founder of Titan CapitalDasha MaggioPartner at Felicis Ventures, writer on venture capital and founder psychologyNancy WangInvestor at Felicis VenturesLeah von SiemensPartner at Manta Ray VenturesEghosa OmoiguiFounder and Managing General Partner at EchoVC Partners
+ 1,413 more
Shared employers
Also worked at XOMA Royalty6
Also worked at RTW Investments, LP17
Kelly BarnumDirector Of Talent at Volition CapitalJohn MaraganoreAdvisor at Oak HC/FTRoderick WongManaging Partner, CIO at RTW Investments L.P.Stephanie SirotaPartner, Chief Business Officer at RTW Investments L.P.Naveen YalamanchiPartner, Portfolio Manager at RTW Investments L.P.Gotham MakkerPartner, Head of Strategic Investments at RTW Investments L.P.
+ 11 more
Also worked at CORXEL Pharmaceuticals2
Also worked at MTS Health Partners12
Bradley SloanManaging Partner at Questa CapitalMichael LudwigPartner at HLM Investment PartnersAkhil AkulaVice President at New Rhein Healthcare Investors, LLCRyan KrausVice President at 1315 CapitalMelanie HarrisHead of Investor Relations at Centerview Capital TechnologyMichael VigilanteVice President, Investments and Business Development at Ligand Pharmaceuticals
+ 6 more



































